Novartis AG vs Western Union Co — how do they compare? Novartis AG trades at $152.26 (market cap $295.37B), while Western Union Co trades at $7.08 (market cap $2.20B). The key difference: Novartis AG is far larger — about 134.3× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.33%). Which is the better fit depends on your goals.
| NVS | WU | |
|---|---|---|
Market Cap | $295.37B | $2.20B |
Sector | Health | Technology |
52-Week High | $168.62 | $10.28 |
52-Week Low | $119.31 | $6.36 |
Enterprise Value | $336.69B | $2.10B |
Dividend Yield | 3.07% | 13.33% |
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Western Union (WU) trades at $7.03, down 0.71% on the day, with a bearish technical outlook and recent earnings misses. The stock shows low valuation multiples (P/E 5.69, P/S 0.56) and strong profitability metrics (ROE 43.97%), but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent news highlights challenges in retail money transfers and a new digital initiative with Rain.
The investment outlook is cautious due to declining revenue, earnings volatility, and bearish analyst sentiment. Opportunities exist from deep value metrics and dividend yield, but risks include competitive pressures and execution challenges in digital transformation. The consensus price target is $7.14, suggesting limited upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →